Log In
Print this Print this

Keyzilen, esketamine hydrochloride (AM-101)

  Manage Alerts
Collapse Summary General Information
Company Auris Medical Holding AG
DescriptionIntratympanicly injected non-competitive antagonist of NMDA receptors
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationTinnitus
Indication DetailsTreat acute peripheral (inner ear) tinnitus; Treat post acute inner ear tinnitus
Regulatory Designation U.S. - Fast Track (Treat acute peripheral (inner ear) tinnitus);
U.S. - Special Protocol Assessment (Treat acute peripheral (inner ear) tinnitus)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today